KNOTUS Co.Ltd Asset Resilience Ratio

Latest as of March 2025: 0.43%

KNOTUS Co.Ltd asset resilience ratio. KNOTUS Co.Ltd (278650) has an Asset Resilience Ratio of 0.43% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KNOTUS Co.Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩683.20 Million
≈ $462.99K USD Cash + Short-term Investments

Total Assets

₩158.65 Billion
≈ $107.52 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of KNOTUS Co.Ltd (2016–2024)

Asset resilience ratio of KNOTUS Co.Ltd from 2016 to 2024. This chart shows how KNOTUS Co.Ltd's Asset Resilience Ratio has changed over time. Read debt load of KNOTUS Co.Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down KNOTUS Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 278650 total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩683.20 Million 0.43%
Total Liquid Assets ₩683.20 Million 0.43%

Asset Resilience Insights

  • Limited Liquidity: KNOTUS Co.Ltd maintains only 0.43% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

KNOTUS Co.Ltd Industry Peers by Asset Resilience Ratio

Compare KNOTUS Co.Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

KNOTUS Co.Ltd Asset Resilience Ratio by Year (2016–2024)

KNOTUS Co.Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for KNOTUS Co.Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 27.83% ₩46.84 Billion
≈ $31.74 Million
₩168.33 Billion
≈ $114.07 Million
-13.15pp
2023-12-31 40.97% ₩70.36 Billion
≈ $47.68 Million
₩171.71 Billion
≈ $116.37 Million
-15.39pp
2022-12-31 56.36% ₩97.05 Billion
≈ $65.77 Million
₩172.19 Billion
≈ $116.69 Million
+45.38pp
2021-12-31 10.98% ₩10.39 Billion
≈ $7.04 Million
₩94.63 Billion
≈ $64.13 Million
-9.11pp
2020-12-31 20.09% ₩14.91 Billion
≈ $10.10 Million
₩74.22 Billion
≈ $50.29 Million
-6.24pp
2019-12-31 26.33% ₩16.20 Billion
≈ $10.98 Million
₩61.53 Billion
≈ $41.70 Million
+17.56pp
2018-12-31 8.78% ₩3.84 Billion
≈ $2.60 Million
₩43.74 Billion
≈ $29.64 Million
-38.63pp
2017-12-31 47.40% ₩15.51 Billion
≈ $10.51 Million
₩32.72 Billion
≈ $22.17 Million
+22.52pp
2016-12-31 24.88% ₩4.86 Billion
≈ $3.29 Million
₩19.53 Billion
≈ $13.23 Million
--
pp = percentage points

About KNOTUS Co.Ltd

KQ:278650 Korea Biotechnology
Market Cap
$290.80 Million
₩429.11 Billion KRW
Market Cap Rank
#14723 Global
#467 in Korea
Share Price
₩5080.00
Change (1 day)
-22.68%
52-Week Range
₩1099.00 - ₩6870.00
All Time High
₩36886.01
About

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more